Targets & Mechanisms


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">Triplet brings a new strategy to Huntington&#x2019;s disease</h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1ef7l34r60">Unveils preclinical POC data for its first DNA damage repair target</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Lauren Martz, Senior Editor&#xA0;</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


Triplet Therapeutics Inc.

Triplet brings a new strategy to Huntington’s disease

Triplet unveils preclinical proof-of-concept data in Huntington’s disease for the company’s first DNA damage repair target.

Unveils preclinical POC data for its first DNA damage repair target

Featured Analysis

Articles

Current Editions

Data Graphics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

Events

My Workspace

Company Overview

Management

Editorial & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><center><span style="font-size:1.75rem;font-weight:500;">Access This Article</span></center>

Paywall Not Entitled Title

Request a Trial

Purchase This Article

<center><span style="font-weight:300;">[Subscribers Log in]{{login}}</span></center>

Paywall Sub log in